ACADIA Pharmaceuticals, Inc. (ACAD)
22.60
+0.51
(+2.31%)
USD |
NASDAQ |
Jun 23, 16:00
22.58
-0.02
(-0.11%)
Pre-Market: 20:00
ACADIA Pharmaceuticals Gross Profit (TTM) : 1.002B for March 31, 2026
Gross Profit (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.002B |
| December 31, 2025 | 982.51M |
| September 30, 2025 | 962.54M |
| June 30, 2025 | 937.10M |
| March 31, 2025 | 917.00M |
| December 31, 2024 | 875.96M |
| September 30, 2024 | 851.31M |
| June 30, 2024 | 816.84M |
| March 31, 2024 | 750.88M |
| December 31, 2023 | 684.80M |
| September 30, 2023 | 605.72M |
| June 30, 2023 | 537.23M |
| March 31, 2023 | 511.35M |
| December 31, 2022 | 507.07M |
| September 30, 2022 | 501.19M |
| June 30, 2022 | 500.14M |
| March 31, 2022 | 480.56M |
| December 31, 2021 | 472.05M |
| September 30, 2021 | 459.19M |
| June 30, 2021 | 449.83M |
| March 31, 2021 | 444.34M |
| December 31, 2020 | 427.24M |
| September 30, 2020 | 404.90M |
| June 30, 2020 | 378.90M |
| March 31, 2020 | 352.31M |
| Date | Value |
|---|---|
| December 31, 2019 | 325.42M |
| September 30, 2019 | 289.17M |
| June 30, 2019 | 251.47M |
| March 31, 2019 | 224.72M |
| December 31, 2018 | 211.43M |
| September 30, 2018 | 195.79M |
| June 30, 2018 | 174.77M |
| March 31, 2018 | 149.52M |
| December 31, 2017 | 115.82M |
| September 30, 2017 | 84.98M |
| June 30, 2017 | 55.96M |
| March 31, 2017 | 27.05M |
| December 31, 2016 | 14.03M |
| September 30, 2016 | 3.769M |
| June 30, 2016 | -0.654M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.465B |
| BioMarin Pharmaceutical, Inc. | 2.508B |
| Catalyst Pharmaceuticals, Inc. | 475.28M |
| Exelixis, Inc. | 2.291B |
| Gilead Sciences, Inc. | 23.65B |